Ironwood appoints Sravan Emany as CFO, effective Dec 6, 2021

IRONWOOD PHARMACEUTICALS INC

Sravan K. Emany named SVP, CFO effective Dec 6, 2021; Jason Rickard remains COO.
Emany previously corporate VP at Integra LifeSciences and managing director at BofA.
Base salary $500k, bonus target 50% of base, $200k sign-on bonus, 85k RSUs and 85k PSUs.
Emany to enter indemnification and executive severance agreement (filed as Exhibit 10.1).

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Sravan K. Emany

Senior Vice President, Chief Financial Officer

IRWD · IRONWOOD PHARMACEUTICALS INC

Effective: 2021-12-06
Filed: December 1, 2021, 6:59 PM ET

On November 29, 2021, the Board of Directors of Ironwood Pharmaceuticals, Inc. (the “Company”) appointed Sravan K. Emany, 44, as the Company’s Senior Vice President, Chief Financial Officer, effective December 6, 2021 (the “Effective Date”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Sravan K. Emany was appointed as Senior Vice President, Chief Financial Officer at IRONWOOD PHARMACEUTICALS INC.

Action: appointed
Role: Senior Vice President, Chief Financial Officer

Exact text from the filing

On November 29, 2021, the Board of Directors of Ironwood Pharmaceuticals, Inc. (the “Company”) appointed Sravan K. Emany, 44, as the Company’s Senior Vice President, Chief Financial Officer, effective December 6, 2021 (the “Effective Date”).

View on SEC.gov

IRONWOOD PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001104659-21-145194

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.